Q&A: Large-scale commercial expansion at Lonza’s Stein facility

[Article Title]

Lonza recently announced a significant capacity expansion at its Stein, Switzerland, drug product facility. This Q&A paper provides more information about the added capabilities, how they complement its existing drug product network, and the benefits the expansion will bring for biopharmaceutical and biotech companies. 

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.